Nasdaq-Listed AGAPE Forges Ahead with Sustainable Energy Business

5 months ago

KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 9, 2023 / Homegrown Nasdaq listed AGAPE ATP Corporation ("ATPC" or the "Company")(NASDAQ:ATPC)…

Radical Imaging Announces Integration of FlexView Inside Agora Care

5 months ago

Integration will enable Agora Care to focus on its strengths in solving today's challenges in long-term storage and access to…

Blue Cross and Blue Shield of Minnesota Foundation Awards $1.5M in Grants; Welcomes Kristine Rhodes to Board of Directors

5 months ago

EAGAN, MN / ACCESSWIRE / November 9, 2023 / The Blue Cross and Blue Shield of Minnesota Foundation has awarded…

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

5 months ago

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),…

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

5 months ago

PharmAla, University of Calgary, and Heroic Hearts Canada to partner on a groundbreaking observational trialVANCOUVER, British Columbia, Nov. 09, 2023…

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

5 months ago

Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 (GLOBE…

Evoke Pharma Reports Third Quarter 2023 Financial Results

5 months ago

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase…

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

5 months ago

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial…

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

5 months ago

-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline…